Home › Nasopharyngeal Carcinoma › New Jersey
Nasopharyngeal Carcinoma clinical trials in New Jersey
3 studies for Nasopharyngeal Carcinoma are looking for participants at sites in New Jersey.
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06029270Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Hackensack University Medical Center, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06980038A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Hackensack University Medical Center, Hackensack
- Jersey Shore Medical Center, Neptune City
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick
- and 1 more
RecruitingPhase 2
Up to age 21 · All sexes · Updated Oct 14, 2026 · NCT06064097From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.